EyeGate Pharmaceuticals Announces Participation at the H.C. Wainwright 20th Annual Global Investment Conference
29 août 2018 08h30 HE
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Aug. 29, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for...
EyeGate Announces Enrollment of First Patient in PRK Pilot Study
20 août 2018 08h30 HE
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Aug. 20, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for...
EyeGate Pharmaceuticals Announces New Board Member, Peter Greenleaf
07 août 2018 08h30 HE
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Aug. 07, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary...
EyeGate Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update
03 août 2018 08h30 HE
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Aug. 03, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage, specialty pharmaceutical company with two proprietary...
EyeGate Announces FDA Approval of Two IDE Submissions for Ocular Bandage Gel
24 juil. 2018 08h30 HE
|
EyeGate Pharmaceuticals, Inc.
FDA Grants Approval for Studies for Patients that have undergone Photorefractive Keratectomy and for Patients with Punctate Epitheliopathies WALTHAM, Mass., July 24, 2018 (GLOBE NEWSWIRE) --...
EyeGate Addresses Final FDA Action Item with Submission of IDE Amendment for Ocular Bandage Gel
22 juin 2018 08h30 HE
|
EyeGate Pharmaceuticals, Inc.
Responses to the last of four outstanding action items submitted; Potential to start clinical study in the Third Quarter of 2018 WALTHAM, Mass., June 22, 2018 (GLOBE NEWSWIRE) -- EyeGate...
EyeGate Files Supplement to Investigational Device Exemption to Commence Study in Punctate Epitheliopathy using the EyeGate Ocular Bandage Gel
30 mai 2018 08h30 HE
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., May 30, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary...
EyeGate Addresses Majority of FDA’s Action Items with Submission of Investigational Device Exemption Amendment for Ocular Bandage Gel
22 mai 2018 08h30 HE
|
EyeGate Pharmaceuticals, Inc.
Responses to three of the four outstanding action items submitted; Response to Fourth action item Expected in the Second Quarter of 2018 with Potential to start clinical study in the Third Quarter of...
EyeGate Pharmaceuticals Announces New Board Member, Steven Boyd
16 mai 2018 16h30 HE
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., May 16, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary...
EyeGate Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update
11 mai 2018 08h30 HE
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., May 11, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary...